GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Dividend Yield %

Pardes Biosciences (Pardes Biosciences) Dividend Yield % : 0.00% (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Dividend Yield %?

As of today (2024-05-27), the Trailing Annual Dividend Yield of Pardes Biosciences is 0.00%.

The historical rank and industry rank for Pardes Biosciences's Dividend Yield % or its related term are showing as below:

PRDS's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5
* Ranked among companies with meaningful Dividend Yield % only.

Pardes Biosciences's Dividend Payout Ratio for the three months ended in Jun. 2023 was 0.00.

As of today (2024-05-27), the Forward Dividend Yield % of Pardes Biosciences is 0.00%.

Pardes Biosciences's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Pardes Biosciences Dividend Yield % Historical Data

The historical data trend for Pardes Biosciences's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pardes Biosciences Dividend Yield % Chart

Pardes Biosciences Annual Data
Trend Dec20 Dec21 Dec22
Dividend Yield %
- - -

Pardes Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pardes Biosciences's Dividend Yield %

For the Biotechnology subindustry, Pardes Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pardes Biosciences's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Pardes Biosciences's Dividend Yield % falls into.



Pardes Biosciences Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Pardes Biosciences  (NAS:PRDS) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Pardes Biosciences Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Pardes Biosciences's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pardes Biosciences (Pardes Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Executives
Fs Development Holdings Ii, Llc 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky officer: Chief Commercial Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans director, officer: Chief Executive Officer
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone director 190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson officer: Chief Financial Officer 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth officer: Chief Business & Strategy Ofcr 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney officer: Chief Development Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin director, officer: President and CEO C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013

Pardes Biosciences (Pardes Biosciences) Headlines